Daiichi Sankyo Signs a Non-Exclusive License Agreement with Ultragenyx for Gene Therapy Manufacturing Technology

Daiichi Sankyo Signs a Non-Exclusive License Agreement with Ultragenyx for Gene Therapy Manufacturing Technology

Shots:

  • Ultragenyx to receive $200m up front including $125M in cash & $75M equity investment at $60/share, $25M on completion of technology transfer the HeLa PCL and HEK293 platforms along with royalties on sales of products manufactured in either system
  • Ultragenyx get a non-exclusive license to IP, including know-how and patent applications, regarding its manufacturing technology platforms for AAV-based gene therapy products
  • Ultragenyx retains the exclusive right to utilize its manufacturing technology for its current target indications and additional indications identified in the future

Click here ­to­ read full press release/ article | Ref: Ultragenyx | Image: Ultragenyx